A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer

NCT03602495 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

204

Enrollment

INDUSTRY

Sponsor class

Stopped Based on IDMC's recommendations during the interim analysis"the trial has reached the goal of early termination of the trial". the sponsor communicating with CDE, CDE agreed to unblind the trial and submit a NDA.

Conditions

Differentiated Thyroid Cancer

Interventions

DRUG: Donafenib
DRUG: Placebo

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd